Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Idiopathic pulmonary fibrosis (IPF) is a fatal disease characterized by progressive and irreversible loss of lung function. CSP7 exerts anti-fibrotic effects on fibrotic lung (myo)fibroblasts, which are the primary effector cells in progressive pulmonary fibrosis (PF) restoring p53-microRNA-34a-feedback induction. However, p53-microRNA-34a's role in the anti-fibrotic effects of Nintedanib and Pirfenidone have not been explored. We compared the effects of oral-gavage-fed standard-of-care anti-fibrotic drugs, Nintedanib or Pirfenidone with CSP7 administered by intraperitoneal injection or airway by dry powder inhalation against bleomycin induced PF using wild-type, p53 flox (p53), microRNA-34a flox (microRNA-34a) and tamoxifen inducible conditional knockout mice lacking p53 (p53) or microRNA-34a (miR-34a) expression in lung fibroblasts. Compared to wild-type or p53 or microRNA-34a mice, p53 and miR-34a mice exhibited more severe post-bleomycin body weight and lung function loss, lower survival, and more extracellular matrix deposition. Although daily treatment of wild-type mice with CSP7 or with Nintedanib or Pirfenidone between day 14-21 post-bleomycin improved survival, body weight and lung function, combination of CSP7 with Nintedanib or Pirfenidone was more effective than either drug. Interestingly, p53- and miR-34a-PF mice resisted these treatments, supporting the importance of restoration of p53-miR-34a-feedback induction in lung (myo)fibroblasts for the anti-fibrotic effects.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1152/ajplung.00295.2024 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Comparative effects of pirfenidone and nintedanib in experimental intraabdominal adhesion model.
Arab J Gastroenterol
September 2025
Sultan 2.Abdul Hamid Khan Educational And Research Hospital, Department of General Surgery, İstanbul, Türkiye.
Background: Postoperative peritoneal adhesions (PPA) develop in up to 90% of intraabdominal surgeries and are a major cause of small bowel obstruction, leading to readmissions and morbidity. However, no effective pharmacologic strategy currently exists for PPA prevention. Pirfenidone and Nintedanib are oral antifibrotics approved for idiopathic pulmonary fibrosis, with emerging data on their effects in cardiac and hepatic fibrosis.
View Article and Find Full Text PDFUpdated systematic literature review and meta-analysis to inform the Italian Society of Rheumatology Recommendations on the treatment of rheumatoid arthritis-associated interstitial lung disease.
Autoimmun Rev
August 2025
University of Modena and Reggio Emilia, Italy; Rheumatology Unit, AUSL-IRCCS Reggio Emilia, Italy.
Background: rheumatoid arthritis-associated interstitial lung disease (RA-ILD) is a severe extra-articular manifestation of rheumatoid arthritis (RA). Despite recent guideline initiatives, no treatment recommendations specifically tailored to RA-ILD have been developed in Italy. This systematic literature review (SLR) and meta-analysis was conducted to inform the Italian Society of Rheumatology (SIR) national recommendations for the management of RA-ILD.
View Article and Find Full Text PDFSignificant Stagnancy in the Search and Use of New Antiarrhythmic Agents With Some Recent Beams of Hope.
Curr Vasc Pharmacol
August 2025
Department of Cardiology, Hippokrateio University Hospital, Athens Greece.
Over the last few decades, there has been noteworthy long-lasting stagnancy in the field of antiarrhythmic drugs (AAD), with the development of novel AAD notably declining over the years. Although ablation therapy has dominated, there remains an unmet need for effective and safe antiarrhythmic therapy in those choosing a conservative approach and those failing the ablation procedure( s). Also, in patients with life-threatening ventricular arrhythmias, in the era of the implantable cardioverter defibrillator dominance, many patients require effective and safe AAD therapy to mitigate the recurrence of arrhythmias and the delivery of painful and unpleasant device shocks.
View Article and Find Full Text PDF3D alveolar organoid drug screening model for targeting TGF-β1 in pulmonary fibrosis.
Biochem Biophys Rep
September 2025
Division of Intractable Diseases, Department of Chronic Diseases Convergence Research, Korea National Institute of Health, Cheongju, 28160, Republic of Korea.
Idiopathic pulmonary fibrosis (IPF) is a prototype of chronic, progressive, and fibrotic lung disease. Excessive deposition of extracellular matrix (ECM) results in fibrotic remodeling, alveolar destruction, and irreversible lung dysfunction. In addition to myofibroblast activation and ECM deposition, repetitive lung epithelial cell damage and reprogramming areconsidered to be closely involved in IPF pathogenesis.
View Article and Find Full Text PDFp53-miR-34a Feedback in Lung Fibroblasts Regulates Antifibrotic Effects of CSP7, Nintedanib and Pirfenidone.
Am J Physiol Lung Cell Mol Physiol
August 2025
Texas Lung Injury Institute, Department of Cellular and Molecular Biology, The University of Texas Health Science Center at Tyler, 11937 US Highway 271, Tyler, TX 75708.
Idiopathic pulmonary fibrosis (IPF) is a fatal disease characterized by progressive and irreversible loss of lung function. CSP7 exerts anti-fibrotic effects on fibrotic lung (myo)fibroblasts, which are the primary effector cells in progressive pulmonary fibrosis (PF) restoring p53-microRNA-34a-feedback induction. However, p53-microRNA-34a's role in the anti-fibrotic effects of Nintedanib and Pirfenidone have not been explored.
View Article and Find Full Text PDF